0001104659-23-122862.txt : 20231201 0001104659-23-122862.hdr.sgml : 20231201 20231201163014 ACCESSION NUMBER: 0001104659-23-122862 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231201 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INVIVO THERAPEUTICS HOLDINGS CORP. CENTRAL INDEX KEY: 0001292519 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37350 FILM NUMBER: 231459962 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 EAST 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-863-5524 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 EAST 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Design Source, Inc. DATE OF NAME CHANGE: 20040602 8-K 1 tm2332011d1_8k.htm FORM 8-K
false 0001292519 0001292519 2023-12-01 2023-12-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 1, 2023

 

 

 

InVivo Therapeutics Holdings Corp.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Nevada 001-37350 36-4528166
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

 

One Kendall Square, Suite B14402

Cambridge, MA 02139

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617) 863-5500

 

N/A 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.00001 par value per share   NVIV   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

 

On December 1, 2023, InVivo Therapeutics Holdings Corp. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”).

 

In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided an initial period of 180 calendar days, or until Wednesday, May 29, 2024 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(G). In addition, if, at any time before the Compliance Date, the bid price for the Company’s common stock closes at $0.10 or less for ten consecutive trading days, the Staff will issue a Staff Delisting Determination under Nasdaq Listing Rule 5810(c)(3)(A)(iii).

 

If the Company does not regain compliance by the end of the compliance period, under Nasdaq Listing Rule 5810(c)(3)(A)(ii), if on the last day of the compliance period the Company is in compliance with the market value of publicly held shares requirement for continued listing as well as all other standards for initial listing of its common stock on The Nasdaq Capital Market (other than the bid price requirement), the Company may be eligible for additional time if the Company also provides written notice to Nasdaq of its intention to cure the deficiency during a second compliance period, by effecting a reverse stock split, if necessary, at which point Nasdaq may grant the Company an additional 180-days to regain compliance with the Bid Price Requirement. 

 

If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock may be delisted. At that time, the Company may appeal the Staff’s delisting determination to the Nasdaq Listing Qualifications Panel (the “Panel”). The Company expects that its common stock would remain listed pending the Panel’s decision. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful.

 

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INVIVO THERAPEUTICS HOLDINGS CORP.
     
Date: December 1, 2023 By:    /s/ Richard Toselli
    Richard Toselli, M.D.
    Chief Executive Officer

 

 

 

 EX-101.SCH 2 nviv-20231201.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 nviv-20231201_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 nviv-20231201_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 01, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 01, 2023
Entity File Number 001-37350
Entity Registrant Name InVivo Therapeutics Holdings Corp.
Entity Central Index Key 0001292519
Entity Tax Identification Number 36-4528166
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One One Kendall Square
Entity Address, Address Line Two Suite B14402
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 863-5500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.00001 par value per share
Trading Symbol NVIV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 tm2332011d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001292519 2023-12-01 2023-12-01 iso4217:USD shares iso4217:USD shares false 0001292519 8-K 2023-12-01 InVivo Therapeutics Holdings Corp. NV 001-37350 36-4528166 One Kendall Square Suite B14402 Cambridge MA 02139 617 863-5500 false false false false Common Stock, $0.00001 par value per share NVIV NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,:#@5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #&@X%7$HIJ)^T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VE!,'1[6?&D(+B@> O)[&ZP:4(RTN[;F\;=+J(/X#$S?[[Y M!J;306H?\3GZ@)$LIIO9#6.2.FS8D2A(@*2/Z%2JGQI:Q;V3&1 M&C7F7\E*.@797)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MQH.!5_!,:I)P! ,1$ !@ !X;"]W;W)KN;L.," MBC.>!=^:@VWB;F6AU(O;F<0#+W!$/.&1=1(,OC9\S)/$*0''][VH5U[3!1YN MOZO?%SAZ)^9+EB7U2VT]\?T,%8*024WR2[>[<=MLC M46ZL2O?!0) *N?MFK_M$' :TC@2$^X"PX-Y=J*"\998-^UIMB79G@YK;*&ZU MB 8X(5U59E;#KP+B['"L-ESW?0M2[H ?[<-N=F'AD;!;'EV0@)Z1, A;_PWW M@:#$"$N,L-!K81CD[]'"6 V%^J>.:*?0KE=PW7MM,A;Q@0?M:;C><&_X\X^T M&_R&\+5*OA:F/KQ540Z]:,G\+>-U<'AX[_PS M$N(=JHR@@(XH+B/F&K.@H\ M?LD2PQ&.3LG1.2T94ZZ%BLF=C DT7VU>&I1<&Q5]U-1(W9*MBRK>22OL&[D7 M"2>/>;JH;VY<(PCH>>NRU0D0GLN2Y_(4GB>^$JZU(6F/+*W-%*XSD<]BH\A\ MS37+>&Y%9'[XI))8R)4A8Z6S"P2V5\+V3H$=0VTU2\A$QOR5?.9O=;BX4@ Y M#*_"#KU"L*Y*K*M3L.;LE4QB8!-+$;'"TX]7&%=L=<_;G;!'NUT$CP:5AP:G M $YD!(50NF [(S,+SP11&LJ30T(AKRJNK7R#^N,S!GE@]/04R%$<@SV:L_<- M\@7.(U]E/1DN"5'0'C)F24)FWW.F,7>AU2R@J)7CI/.MJB7%)6>Y@%KMW7>Z038$*/58*"XGW_3PEHN(3%I MFLN]_9I:*ERH:0U"JZ% <0^?J41$PL( ) _0WEJPI)8'5VGB":LA$.(V/=7\ M/(+T<'B^=DM%<$98U'Y=+NOKUZ#72%8Y?XC;]/_()L;D0-8(B,LV AXL_G%W MG@L+RS6U)#3\9?$KF?$HAWZK778T*+G^A'7!S*KHY8S\%%P$;B5",J;)AB4Y M)QG2*'UUG-@@]CF:WHS\PILKKPY.\_B[E>N6R]#LHV+7SD(S)^NKB@D<[SC]X M 79_)CPP=T5#$KX$H>#B$G3U[OU\MV-55KP3+Y2%-^QB<\T9/ WN!/A]J91] MWW&OV>6_),-_ 5!+ P04 " #&@X%7GZ ;\+$" #B# #0 'AL+W-T M>6QEO%DN7/Z MZZ>S;"=I=67=A['-HN M6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2 MK"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP( M&K XU7=>&18/QA<0&>7= MJ?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N- M9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W] MK;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LU MF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ> MDO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A M'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/ M9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@> MF*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%' M, ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " #&@X%7EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( ,:#@5>J MQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A M#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B M;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X" M$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S; M%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z M0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&) M)@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y> M9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " #&@X%7)!Z;HJT #X M 0 &@ 'AL+U]R96QS+W=O[IFBG#S^0W1U MW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@ M;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ QH.!5V60>9(9 M 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL M6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4 M'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY M'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?K MT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y; M@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$" M% ,4 " #&@X%7!T%-8H$ "Q $ @ $ 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( ,:#@5<2BFHG[0 "L" 1 M " :\ !D;V-097)PC$ 8 )PG 3 " &UL4$L! A0#% @ QH.!5_!,:I)P! ,1$ !@ M ("!# @ 'AL+W=O?H!OPL0( .(, - " ;(, !X;"]S='EL97,N>&UL M4$L! A0#% @ QH.!5Y>*NQS $P( L ( !C@\ M %]R96QS+RYR96QS4$L! A0#% @ QH.!5ZK$(A8S 0 (@( \ M ( !=Q 'AL+W=O7!E&UL4$L%!@ ) D /@( ' 84 $! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://invivotherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nviv-20231201.xsd nviv-20231201_lab.xml nviv-20231201_pre.xml tm2332011d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2332011d1_8k.htm": { "nsprefix": "nviv", "nsuri": "http://invivotherapeutics.com/20231201", "dts": { "schema": { "local": [ "nviv-20231201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nviv-20231201_lab.xml" ] }, "presentationLink": { "local": [ "nviv-20231201_pre.xml" ] }, "inline": { "local": [ "tm2332011d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://invivotherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332011d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332011d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://invivotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001104659-23-122862-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-122862-xbrl.zip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end